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Introduction
Preeclampsia is a maternal hypertensive dis-
ease affecting 7–10% of all first-time pregnan-
cies. It is characterized by hypertension, pro-
Abstract
Background: Pregnancy is characterized by an 
inflammatory-like process and this may be exacer-
bated in preeclampsia. The heme oxygenase (HO)
enzymes generate carbon monoxide (CO) that in-
duces blood vessel relaxation and biliverdin that
acts as an endogenous antioxidant.
Materials and Methods: We examined the expres-
sion and localization of HO-1 and HO-2 in normal
and preeclamptic placenta using reverse transcription
polymerase chain reaction (RT-PCR), RNase protec-
tion assay, immunoblotting and immunohistochem-
istry. In addition, the effect of HO activation on tumor
necrosis factor-alpha (TNF) induced placental dam-
age and on feto-placental circulation was studied.
Results: We provide the first evidence for the role of
HO as an endogenous placental factor involved with
cytoprotection and placental blood vessel relaxation.
HO-1 was significantly higher at term, compared
with first trimester placentae indicating its role in
placental vascular development and regulation. HO-1
predominantly localized in the extravascular connec-
tive tissue that forms the perivascular contractile
sheath around the developing blood vessels. HO-2
was localized in the capillaries, as well as the villous
stroma, with weak staining of trophoblast. Induction
of HO-1 caused a significant attenuation of TNF-
mediated cellular damage in placental villous ex-
plants, as assessed by lactate dehydrogenase leakage
(p  0.01). HO-1 protein was significantly reduced 
in placentae from pregnancies complicated with pre-
eclampsia, compared with gestationally matched nor-
mal pregnancies. This suggests that the impairment
of HO-1 activation may compromise the compen-
satory mechanism and predispose the placenta to 
cellular injury and subsequent maternal endothelial
cell activation. Isometric contractility studies showed
that hemin reduced vascular tension by 61% in
U46619-preconstricted placental arteries. Hemin-
induced vessel relaxation and CO production was in-
hibited by HO inhibitor, tin protoporphyrin IX.
Conclusions: Our findings establish HO-1 as an en-
dogenous system that offers protection against cyto-
toxic damage in the placenta, identifies the HO-CO
pathway to regulate feto-placental circulation and
provides a new approach to study the disease of
preeclampsia.
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teinuria, reduced utero-placental circulation
and endothelial cell dysfunction. It is a major
cause of maternal death and contributes signif-
icantly to perinatal morbidity. Moreover,
women with prior preeclampsia are character-
ized by hyperinsulinemia and a 2- to 3-fold ex-
cess risk of hypertension and ischemic heart
disease in later life (1,2). Preeclampsia is asso-
ciated with reduced utero-placental circulation
leading to poor placental perfusion, local hy-
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poxia and secretion of cytotoxic factors into the
maternal blood with consequent widespread
circulatory disturbances secondary to endothe-
lial dysfunction (3). The cause of preeclampsia
is unknown. The placenta is implicated since
the delivery of the placenta is the only known
cure for this disease. Although the identity of
any specific cytotoxic factor is unknown,
preeclamptic sera can cause endothelial dys-
function and inhibit the ability of vasorelax-
ants to relax preconstricted blood vessels (4).
The major research efforts have concentrated on
identifying factors for the initiation and main-
tenance of the pathological processes in
preeclampsia. Recently, it was suggested that
preeclampsia is a disease of exacerbation of an
inflammatory process characteristic of normal
pregnancy, but lacking a compensatory system
(5). Tumor necrosis factor-alpha (TNF), a cy-
tokine produced mainly by macrophages, is in-
volved in the induction of oxygen free radicals
(6). The level of TNF in the maternal circula-
tion is increased prior to the clinical manifesta-
tion of preeclampsia. In addition, placental
TNF protein and mRNA expression are re-
ported to be elevated and to correlate with in-
creased placental lipid peroxidation in this dis-
order (6), supporting the role of this cytokine
in the endothelial dysfunction noted in
preeclampsia. Little is known about the role of
endogenous placental factors that may be re-
sponsible for counteracting the inflammatory
response of pregnancy.
Activation of the microsomal enzymes
heme oxygenases (HO) appears to offer cellu-
lar protection (7). Degradation of heme by HO
generates carbon monoxide (CO), together
with biliverdin (an antioxidant) and free iron
(a gene regulator). Two main isozymes of HO
are HO-1 (inducible) and HO-2 (constitutive).
The HO-2 is present in high concentration in
brain, testis and vascular endothelium;
whereas, HO-1 is widely distributed in the
body (7). In a human case of HO-1 deficiency,
there is severe, persistent endothelial damage,
as indicated by marked elevation in thrombo-
modulin and von Willerand factor (8). It was
suggested that the induction of HO-1 directly
regulates endothelial cell activation, as it pre-
vented the oxidative stress-induced expres-
sion of adhesion molecules (9,10). Like nitric
oxide (NO), carbon monoxide (CO) is an en-
dogenously produced vasorelaxant molecule
that activates soluble guanylate cyclase lead-
ing to an increase in intracellular guanosine
3’,5’-cyclic monophosphate (cGMP) (11). Ex-
ogenous CO induces vascular smooth muscle
relaxation (12) and regulates blood pressure
in rats (13). Unlike nitric oxide synthase
(NOS), HO-1 activation exerts protection in
various oxidative stress conditions (14). The
products of HO-1 activation are thought to 
act as potent endogenous factors for the 
resolution of stress-induced inflammatory in-
jury (15–17).
The control of feto-placental circulation is
unique, since it lacks autonomic innervation
(18). The vasomotor regulation of the smooth
muscle cells surrounding the villous arterioles
plays a pivotal role in maintaining the blood
flow within the placenta. A variety of circulat-
ing and local substances regulate vasomotor
control of the smooth muscle surrounding the
stem villous arterioles within the placenta
vasculature (19–24). A physiological role for
nitric oxide (NO) in the regulation of vascular
tone was supported by the observation that
NO maintained low vascular tone in the feto-
placental circulation of the isolated, dual-
perfused human cotyledon in vitro (19,20). 
Under hypoxia, however, NO production and
endothelial nitric oxide synthase (eNOS) ex-
pression are suppressed (25–27) and the ves-
sel tone is then probably modulated by hy-
poxia mediated factors. HO-1 is induced
rapidly after oxidative stress conditions, such
as hypoxia (28,29). Moreover, exogenous CO
was shown to counteract the stimulating 
effect of hypoxia on the transcription of a
number of genes, including erytropoietin, en-
dothelin, platelet-derived growth factor-B and
vascular endothelial growth factor in endothe-
lial cells (7).
This study provides the first evidence to
support a role for heme oxygenase (HO) as an
endogenous cytoprotective pathway in human
placenta that is responsible for counteracting the
physiopathological insults during pregnancy. It
shows that HO-1 exhibits a highly specific pat-
tern of expression during placental vascular
evolution and that HO-1 expression is reduced
in placental tissue obtained from pregnancies
complicated by preeclampsia. This indicates
that placenta from such pregnancies may lack
the compensatory mechanism to increased shear
stress. It also demonstrates that the HO-CO
system acts as a local physiological vasoregula-
tor of the feto-placental circulation, thus provid-
ing a new approach for pharmacological ma-
nipulation that may have therapeutic relevance.
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Materials and Methods
Materials and Drug Preparation
All chemicals were obtained from Sigma Chem-
ical Co. Ltd. (Poole, Dorset, U.K.) or as other-
wise cited. Rabbit polyclonal anti-HO-1 and
anti-HO-2 were purchased from StressGen
Biotechnologies Corporation (Victoria, Canada).
Hemin, tin protoporphyrin IX (SnPP), and 
hemoglobin were dissolved in 0.1 M NaOH, to
which phenol-free Dulbecco’s modified Eagle’s
medium (DMEM) or Krebs solution was 
added, and the pH was adjusted to 7.4. All
reagents were prepared and stored in the dark.
NG-methyl-L-arginine (L-NMA) was dissolved
in Krebs solution.
Tissue Collection
Placental biopsies were obtained after termina-
tion (first trimester: 7–12 weeks of gestation;
second trimester: 15–22 weeks) and after elec-
tive Caesarean sections from normal pregnan-
cies at third trimester (27–35 weeks of gesta-
tion) or at term (37–40 weeks of gestation).
Placental biopsies were obtained from preg-
nancies complicated with preeclampsia (27–34
weeks of gestation) and those complicated
with severe intrauterine growth restriction
(IUGR; 33–38 weeks of gestation). Preeclamp-
sia was diagnosed when blood pressure was at
least 140/90 mmHg or greater in a previously
normotensive woman after 20 weeks gestation,
and that there was at least 300 mg/day protein-
uria, platelet count 150,000/ml and urate
350 mmol/l. At least two such blood pressure
recordings were obtained on consecutive occa-
sions, 4 hr apart. All subjects in the preeclamp-
sia group were investigated in the puerperium
to ensure that they were normotensive with no
significant proteinuria at 20 weeks post-
delivery. IUGR placental tissues were obtained
from women with absent end diastolic flow ve-
locity and small-for-dates babies with fetal
weight less than the fifth percentile for gesta-
tional age. Placental tissues were taken from a
central location, lying between the basal and
chorionic plates. Amnion and chorion (chori-
onic laeve) were from reflected membranes
formerly covering the decidua parietalis of the
uterus. Fetal membranes were separated man-
ually and washed in ice-cold sterile normal
saline. Tissues were immersed in 10%
formaldehyde or snap-frozen in liquid nitrogen
immediately after collection. Ethical committee
approval for tissue collection was obtained
from the South Birmingham Ethical Com-
mittee.
Tissue and Cell Preparation
For tissue explant experiments, a full cotyle-
don was biopsied, the maternal side was dis-
sected and the tissue collected in ice-cold 
phenol-red free DMEM. Villous fragments or
chorio-decidua were obtained by gentle dissec-
tion of the tissue. The fragments were equili-
brated for 6 hr in phenol-free DME medium
containing 0.1% bovine serum albumin (BSA),
1% L-glutamine, and 1% antibiotic mixture
(5,000 IU/ml penicillin and 5000 g/ml strep-
tomycin) at 37C in a 95% O2/5% CO2 incuba-
tor. Spontaneously transformed first-trimester
cytotrophoblast-like cell line (ED27) generated
by repeated passaging of trophoblast obtained
from first-trimester tissue by chorionic villous
sampling was a gift from Dr. D. A. Kniss. First-
trimester trophoblast cells were maintained at
37C in a 95% O2/5% CO2 incubator, in 175 cm
2
flasks, in a 1:1 mixture of DMEM, Hams F-12
nutrient mixture (DMEM/Ham-F-12). DMEM/
Ham-F-12 nutrient mixture also contained
15% (volume per volume; v/v) fetal calf serum,
1% L-glutamine, and 1% antibiotic mixture
(5,000 IU/ml penicillin and 5000 g/ml 
streptomycin). Confluent monolayers were
trypsinized with EDTA-trypsin. Cells were
plated at 150  103 cells/well in 24-well plates
for experimental procedures. Monolayers at
over 80% confluence were serum-starved in
serum-free DMEM/F-12 containing 0.1% BSA
for 24 hr.
Amplification of Placental HO-1 and HO-2 
cDNA Fragments
Total RNA from full-thickness term placenta, 
first-trimester tissue, fetal membranes and
first-trimester human trophoblast cells were
prepared using RNAzol® and quantified spec-
trophotometrically at 260 nm. HO-1 and HO-2
cDNAs were synthesised from 5 g of total
RNA by reverse transcription (RT) using 
oligo d(T) and, then, amplified by polymerase
chain reaction (PCR) with the SuperScript®
pre-amplification system (Life Technologies
Ltd., Paisley, U.K.) in 35 thermal cycles as
described previously (30). Primers were de-
signed according to the published sequence of
human monocyte HO-1 and rat testis HO-2.
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The forward (5’-GAATTCAGCATGCCCCAG-
GATTTG-3’) and the reverse (5’-TCTAGAC-
TAGCTGGATGTTGAGCAGGA-3’) primers for
HO-1 were used to amplify a 615-bp fragment,
and the forward (5’-GAATTCGGGACCAAG-
GAAGCACAT-3’) and the reverse (5’-TCTA-
GACTATGTAGTACCAGGCCAAGA-3’) primers
for HO-2 were used to amplify a 828-bp frag-
ment. The PCR products were subcloned and 
sequenced to confirm their identity (30). To en-
sure that RNA was free of genomic DNA, total
RNA was also treated with RNase-free DNase1.
Total RNA from rat brain was used as positive
control.
RNase Protection Assays
Total RNA was isolated from snap frozen pla-
cental tissue by homogenization in guani-
dinium isothiocyanate, followed by acidic
phenol/chloroform extraction. The human
HO-1 probe template consisted of a cDNA
fragment in the vector pCRScript (Stratagene,
Amsterdam, Netherlands), corresponding to nu-
cleotides 883–1242 of the sequence described by
Yoshida et al. (31). HO-1 antisense RNA was
transcribed by T3 RNA polymerase after lin-
earization with XhoI, in the presence of [32P]-
UTP (Amersham, Buckinghamshire, UK), using
standard methods, and on hybridization, pro-
tected a 359-nucleotide fragment.
A probe for human -actin was used as
an internal standard and transcribed from 
the pTRI--Actin-125-Human antisense con-
trol template (Ambion, Witney, Oxon, UK)
with T3 RNA polymerase. On hybridization,
this probe protected a 127-nucleotide frag-
ment. Probes for HO-1 (1.0–5.0  105 cpm),
and -actin (1.0–5.0  104 cpm) were com-
bined with 10 g of total placental RNA and
coprecipitated. RNase protection assays were
then performed using the RPA II kit (Am-
bion, Witney, Oxon), according to the manu-
facturers instructions. Protected fragments
were resolved on 6% denaturing polyacry-
lamide gel electrophoresis (PAGE) gels,
transferred to Whatmann 3 mm paper and
dried under vacuum in a gel drier. Autoradi-
ography was performed using X-ray film
(Kodak Biomax MR, New York, NY) with in-
tensifying screeens a 70C for 2–3 days. Af-
ter autoradiography, the intensities of HO-1-
protected species and their respective -actin
signals were quantitated using the Gelbase
densitometry software.
Western Blots Analysis
Total protein was extracted from tissue in 
high-salt buffer [0.4 M KCl, 20 mM N-2-
hydroxyethylpiperazine-N-2-ethane sulfonic
acid (HEPES), 1 mM DL-Dithiothreitol 
(DTT), 20% glycerol, 0.5 mg/ml bacitracin, 40
mg/ml phenylmethylsulfonyl fluoride (PMSF),
5 mg/ml pepstatin, 5 mg/ml leupeptin]. An
equal amount of total protein (100 g) for each
sample was loaded in 10% sodium dodecyl
sulfate (SDS)-polyacrylamide mini-gel and
separated by electrophoresis. Proteins from the
gels were electro-transferred to prewetted ni-
trocellulose membrane (Amersham, Bucks,
UK) and subjected to immunoblot analysis.
The membranes were blocked in Tris-buffered
saline containing 1% Tween-20, 10% dry
skimmed milk, 5% BSA, and 2% goat serum
for 1 hr to prevent nonspecific binding of the
antibodies. Membranes were then incubated
with either a polyclonal rabbit anti-rat HO-1
(1 : 1000) or a polyclonal rabbit anti-rat HO-2
(1 : 1000) antibodies (StressGen Biotechnolo-
gies Corp., Victoria, Canada). Bands were de-
tected with the nonradioactive enhanced
chemiluminescent protein (ECL) Western Blot-
ting System (Amersham), exposing the mem-
branes to X-ray film (X-Omat AR, Eastman Ko-
dak Company, New York, NY) to record
chemiluminescence and bands were quanti-
tated using a laser densitometer UVP Image-
Store 5000 combine system (UVP Ltd., Cam-
bridge, UK). Recombinant protein was used as
positive control. Protein determination was
carried out by the Bio-Rad protein assay (Bio-
Rad Laboratories Ltd., Herts, UK) using bovine
serum albumin (BSA) as standard.
Lactate Dehydrogenase Assay
Cytotoxicity can be measured as leakage of lac-
tate dehydrogenase (LD) into the culture
medium from tissues (30,32). The cytotoxicity
index was expressed as a percentage ratio of
LD leakage into media/LD in tissue (LDm/LDt).
Placental villous fragments were equilibrated
for 6 hr in phenol-free DME medium contain-
ing 0.1% BSA, 1% L-glutamine, and 1% an-
tibiotic mixture at 37C in a 95% O2/5% CO2
incubator. After overnight exposure of tis-
sue explants to vehicle (control) or TNF
(50 ng/ml) in the absence and presence of
hemin (5 M) or SnPP (20 M), tissue was ho-
mogenized and 100 l aliquots of the ho-
mogenates and 100 l of explant media were
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mixed with LD reagent (Sigma Diagnostics, St
Louis, MO). LD activity was measured using an
UV DU640 spectrophotometer (Beckman Instru-
ments Inc., Fullerton, CA). The rate of increase
in the absorbance at 340 nm due to NADH for-
mation was recorded for 60 sec to give LD ac-
tivity expressed as U/L. The cytotoxicity index
was expressed as the ratio of LDm/LDt.
Immunohistochemistry
Serial 8-m formalin-fixed, wax-embedded
term placental (n 	 6) and first-trimester (n 	
4) sections were immunostained for HO-1 and
HO-2 as previously described (30). Sections
were incubated with the primary antibodies
(HO-1 or HO-2) at a 1 : 500 dilution in PBS
containing 10% normal goat serum and 0.3%
Triton X-100 for 1 hr at room temperature. Am-
plification of primary antibody reaction was
achieved by incubation of sections with a goat
anti-rabbit secondary antibody (DAKO Ltd.,
Bucks, UK) followed by a complex of strepta-
vidin/biotinylated peroxidase (DAKO Ltd.)
Binding was visualized by incubation of sec-
tions in 0.5 mg/ml diaminobenzidine and
0.01% H2O2 in PBS. Sections were counter-
stained with Mayer’s haematoxylin (Raymond
A. Lamb, London, UK), dehydrated and
mounted. Consecutive sections were incubated
in 10% normal goat serum in PBS for 1 hr at
room temperature, in the absence of the pri-
mary antibody as negative control. Adsorption
experiments were performed on anti-HO-1 and
anti-HO-2 to confirm the specificity of antibody
binding. The immunostaining protocol was re-
peated using adsorbed antisera in parallel. 
Adsorption was achieved by incubation of 
primary antibodies (diluted to a final 
concentration of 10 g/ml) overnight at 37C
with purified HO-1 and HO-2 proteins (Stress-
Gen Biotechnologies Corp.), respectively. Con-
secutive sections were immunostained for -
actin-1 (AutogenBioclear Ltd., Wiltshire, UK),
which confirmed that the immunoreactive cells
for HO-1 and HO-2 were smooth muscle-like
cells.
An arbitrary 4-point scale was used to
grade the intensity and the proportion of posi-
tively stained cells. A score of four-plus
() indicated very intense staining of
more than 95% of cells, compared with a score
of minus (), which indicated an absence of
staining. A score of one-to three-plus indicated
slight (), moderate (), and strong ()
staining, respectively. Both immunohistochem-
istry and the scoring of positively stained cells
were performed by a single individual, with-
out prior knowledge of the HO antibodies used
for the study.
Contractility Studies in Placental Vessels
Tissue samples of placental vessels were
obtained from term elective Caesarian sec-
tions. The second or third branches of placen-
tal arteries (approx. 3 mm in diameter) were
carefully isolated and immersed in the ice-
cold Krebs solution (composition in mM:
NaCl 118, KCl 4.75, KH2PO4 1.2, MgSO4 1.2,
CaCl2 2.5, NaHCO3 25, glucose 11). The ves-
sels were cleared of excess connective tissue
and blood traces and dissected into 3 mm-
long rings. Two adjacent rings from the same
vessel were secured separately for control and
test substances in two separate organ baths.
This was achieved using two stainless steel
hooks, one of which was fixed and the other at-
tached to an isometric transducer as described
previously (30). The isometric changes in ten-
sion were recorded through the transducer to
a pen-recorder (Harvard Universal Oscillo-
graph). The organ baths were filled to a
volume of 1 ml with Krebs solution and
gassed with a 95% O2 and 5% CO2 mixture.
The temperature of organ baths was main-
tained at 37C by using an outer water bath.
The vessels were adjusted to a tension of 
300 mg and were allowed to equilibrate for
60 min, during which the Krebs solution was
changed at 15 min intervals and the tension
repeatedly readjusted. KCl (75 mM) was ap-
plied during the experiments to prove the
contractility of the vessels. To examine the va-
sorelaxant effect of hemin, the vessels were
first preconstricted with 107 M U46619, a
thromboxane A2 mimetic. This dose was pre-
viously shown to cause 70% of maximal con-
tractile response, compared with 75 mM KCl.
Hemin (5 M) was added when the placen-
tal artery reached a contractile plateau. In 
selected experiments, the effects of SnPP 
(20 M), a selective HO inhibitor, or of 
L-NMA (1 mM), a NOS inhibitor, on hemin-
induced relaxation were tested. Hemin was
added to the vessels after the addition of the
inhibitors, when the vessels had reached a
new steady-state. In the absence of changes in
tension, hemin was added after 30 min. The
changes in tension by the drugs were com-
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pared with the previous contraction induced
by 107 M of U46619.
Measurement of Carboxy-hemoglobin in 
Conditioned Media
Production of CO was determined in term pla-
cental villous explants, fetal membranes and
first-trimester trophoblast cells by the estima-
tion of the proportion of carboxy-hemoglobin
(COHb) in the media as previously described
(29,33). Samples were stimulated with vehicle
(control), 5 M hemin, 20 M SnPP and hemin
plus SnPP in phenol-free DMEM/F12 contain-
ing 0.1% BSA for the time indicated. Hemoglo-
bin (50 M) was then added for the last hour
of incubation. At the end of the incubation, 
100 l of sample was added to 1150 l of 0.1 M
potassium phosphate buffer containing sodium
hydrosulfite (Na2S2O4) in a cuvette. After 10
min incubation in the dark, absorbance was
read at 420 nm and 433 nm in an UV DU640
spectrophotometer (Beckman Instruments Inc.,
Fullerton, CA). Absorbance values were used
to determine %COHb per mg/ml of total pro-
tein using the formula given below:
%COHb 	 1  (AR  F1)
 AR (F2  F1)
 F3  1
where: AR is the ratio of A420
 A432 of the sam-
ple; and F1, F2, and F3 are constant (F1 	 1.330;
F2 	 0.4787; F3 	 1.9939).
Results
Expression of HO-1 and HO-2 in Human Placenta
RT-PCR analysis revealed that mRNAs encod-
ing both HO-1 and HO-2 were expressed in
first-trimester and term placenta, as well as fe-
tal membranes (Fig. 1A). The expected cDNA
fragments of 615 bp for HO-1 and 815 bp for
HO-2 were amplified from total RNA extracted
from first-trimester and term placenta, and fetal
membranes (Fig. 1A). HO-1 and HO-2 mRNA
were also expressed in cultured first-trimester
human trophoblast (Fig. 1B). Positive control
used for HO-1 was total RNA from rat spleen
(RS) and for HO-2 rat brain (RB).
Western blots analysis demonstrated the
expression of HO-1 (32 kDa heat-shock pro-
tein) immunoreactive protein in human pla-
centa and fetal membranes (Fig. 2A). Corre-
sponding laser densitometric analysis revealed
that the inducible HO-1 protein expression
Fig. 1. Amplification of inducible heme oxyge-
nase (HO-1) and constitutive heme oxygenase
(HO-2) mRNA by reverse transcription poly-
merase chain reaction (RT-PCR) in human pla-
centa, fetal membranes and first-trimester hu-
man trophoblast cells. A 625-bp fragment
corresponding to HO-1 and a 828-bp fragment cor-
responding to HO-2 were amplified from 5 g of 
total RNA. (A) Term placenta (1); first trimester 
tissue (2); amnion (3) and chorio-decidua (4). 
(B) First trimester human trophoblast cells (Troph).
Total RNA from rat spleen (RS) and brain (RB)
served as positive control for HO-1 and HO-2, 
respectively. To ensure that RNA was free of 
genomic DNA, total RNA was treated with RNase-
free DNase1. M, 100-bp ladder.
Fig. 2. Western blots analysis for heme oxyge-
nases in human placenta and fetal membranes.
(A) expression of inducible heme oxygenase (HO-
1; 32 kDa heat shock protein) proteins in amnion
(A), chorio-decidua (Ch-D), term placenta (Term)
and first-trimester tissue (FT). (B) Corresponding
laser densitometric analysis for HO-1. Recombinant
protein (RP) was used as positive control. * p 
0.05 vs first trimester. n 	 6.
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was 2.6-fold higher in full-thick placentae at
term, compared with first-trimester tissues
(Fig. 2B; p  0.05, n 	 6). The level of HO-1
protein expression between amnion and
chorio-decidua samples at term showed no sig-
nificant difference and was similar to that ob-
served in the full-thick placenta samples at
term (Fig. 2B; n 	 6). There was no significant
difference in the level of expression of HO-2
among these tissues (data not shown).
Levels of HO-1 mRNA were determined
throughout gestation using RNAse protection
assay (Fig. 3A). Quantitation of autoradi-
ographic signals by densitometric analysis of
HO-1/-actin ratios showed relatively low
abundance of placental HO-1 mRNA in early
pregnancy (7–12 weeks gestation) (Fig. 3B).
Fig. 3. Quantification of placental inducible
heme oxygenase (HO-1) during early and late
gestation and in preeclampsia. (A) Levels of HO-
1 detected in first trimester (FT), second trimester
(ST) and third trimester (TT) and gestationally
matched preeclamptic (PE) placenta. -actin in
each sample was used as an internal standard for
the estimation of abundance of mRNA. RNAse pro-
tection assay was performed on samples of 10 g
total RNA isolated from human placenta at various
stages of gestation. No protected bands were de-
tected in the negative control with 10 g yeast total
The level of HO-1 mRNA expression in-
creased with increasing gestation and reached
a significant increase during third trimester
(27–34 weeks gestation), compared with
early pregnancy (Fig. 3B). In pregnancies
complicated with preeclampsia, HO-1 mRNA
levels showed no significant change (Fig. 3A
and B). However, HO-1 protein expression
was significantly reduced, compared with
gestationally matched normal third trimester
pregnancies (Fig. 3C–D; p  0.01, n 	 5). In
contrast, placental HO-1 protein was not 
reduced in pregnancies complicated with 
intrauterine growth restriction (IUGR), com-
pared with normal pregnancies (Fig. 3; p 
0.01, n 	 4). No apparent change was seen in
the expression of HO-2 protein in normal,
RNA (not shown). (B) Graphical representation of
HO-1/actin mRNA from the above experiment. Au-
toradiographic signals for HO-1 and actin are ex-
pressed as relative densitometric units. (C) Western
blots analysis for HO-1 in third trimester (TT) and
gestationally matched preeclamptic (PE) and uter-
ine growth-restricted (IUGR) pregnancies. Expres-
sion of HO-1 is shown as 32 kDa heat shock pro-
tein. (D) Corresponding laser densitometric
analysis for HO-1. Recombinant protein (RP) was
used as positive control. *p  0.05 vs FT; **p  0.01
vs TT, n 	 4.
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preeclamptic and IUGR pregnancies (data not
shown).
Effect of Hemin on TNF-induced Lactate
Dehydrogenase Leakage
Term placental villous explants were incubated
overnight with 50 ng/ml TNF in the presence
or absence of hemin to evaluate the cytoprotec-
tive role of HO-1 in placental villi. TNF
caused cellular damage, as measured by the in-
creased leakage of lactate dehydrogenase (LD)
into the media (Fig. 4A; p  0.001, n 	 8). The
cytotoxicity index (LDm/LDt) was significantly
reduced when the villous explants were prein-
cubated with 5 M hemin for 2 hr prior to the
Fig. 4. Effect of hemin on tumor necrosis 
factor-alpha (TNF)-induced cytotoxicity. Vil-
lous fragments from term (A) and preeclamptic (B)
placenta were exposed to vehicle (open column), 
5 M hemin (solid column), 50 ng/ml TNF alone
(crossed column) and TNF added after 2 hr prein-
cubation of villous fragments with 5 M hemin
(dotted column). The insert in (A) shows Western
blots for HO-1 protein expression in villous ex-
plants exposed to hemin and/or TNF for 24 hr.
(C) Villous fragments were incubated with either
vehicle (Veh), 5 M hemin, 20 M tin protopor-
addition of TNF (Fig. 4A; p  0.001, n 	 8).
Western blots analysis showed that, in the
presence of TNF, hemin caused an up-
regulation of HO-1 expression, compared with
TNF (see insert in Fig. 4A). In contrast, TNF
itself decreased HO-1 expression, compared
with contol or hemin. When preeclamptic vil-
lous fragments were treated as in A, it was ap-
parent that under basal conditions the level of
LD leakage was three times higher than in nor-
mal villous explants (Fig. 4B; n 	 3). Hemin
failed to offer any protection and TNF did not
exacerbate the condition. To assess that the pro-
tective effect of hemin was due to HO pathway,
tissue were preincubated with the HO in-
phyri IX (SnPP), and 50 ng/ml TNF. In addition,
TNF was added after 2 hr preincubation of villous
fragments with 5 M hemin, SnPP alone and 
SnPP incubated for 60 min prior to the addition of
hemin. In the presence of SnPP, the protective effect
of hemin on TNF-induced damage was totally
abolished. The cytotoxicity index is expressed as a
percentage ratio of lactate dehydrogenase (LD) leak-
age into media/LD in tissue (LDm/LDt). A value of
less then 5% was considered as viable tissue. Data
represents the mean ( S.E.M.) of eight separate 
experiments performed in duplicate.
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weaker staining of the endothelium of larger
vessels and weak staining of cells in the media
of the muscularized vessels. HO-1 and HO-2
positivity of the decidua was intense in early
pregnancy and appeared to decline at term of
gestation (Table 1).
Effect of Hemin on the Placental 
Vascular Contractility
Placental vessel contractile activity was as-
sessed using villous arterial rings mounted
for isometric recording under 300 mg ten-
sion and allowed to equilibrate for 60 min.
Figure 6 shows the time-course profile of the
contraction of placental arterial vessels fol-
lowing the addition of a thromboxane A2
mimetic, U46619. A rapid and prolonged 
contraction in arterial rings was induced by
100 nM U46619 with an EC50 value of 2.5 
108 M and Emax value of 95% of 75 mM-
KCl. Addition of hemin (5 M) to the pre-
constricted arterial rings caused a rapid fall 
in tension; whereas, contractile activity was
maintained constant in control experiments
using vehicle alone (Fig. 6). The insert 
shows that hemin induced over 60% reduc-
tion in tension at 30 min incubation time-
point (p  0.05, n 	 5).
To test that the hemin-induced human pla-
cental vessel relaxation was due to the activa-
tion of the HO pathway, placental vessels were
preincubated with the HO inhibitor, SnPP, for
30 min prior to the addition of hemin. Figure
7A shows that SnPP prevented a hemin-
induced fall in tension in human placental ves-
sels preconstricted with U46619. Interestingly,
a 15% reduction in tension by hemin on these
preconstricted vessels was still observed in the
presence of SnPP; whereas, the addition of
SnPP itself did not alter vessel tension induced
by U46619 (Fig. 7A).
The involvement of the NO pathway in the
HO-mediated relaxation was investigated by
preincubating preconstricted placental vessels
with 1mM L-NMA for 60 min, prior to the ad-
dition of 5 M hemin. Addition of L-NMA it-
self did not alter vessel tension induced by
U46619. L-NMA was also unable to prevent a
hemin-induced fall in tension in human pla-
cental vessels preconstricted with U46619, be-
cause hemin induced a 60% and 54% fall in
tension in the absence and presence of L-NMA,
respectively (Fig. 7B and C; n 	 4). In contrast,
hemin-induced relaxation of these vessels was
hibitor SnPP (20 M) for 60 min prior to the
addition of hemin. In the presence of SnPP, the
protective effect of hemin on TNF-induced
damage was totally abolished (Fig 4C; n 	 4).
Incubation with 5 M hemin or with 20 M
SnPP overnight did not increase LD leakage
significantly, as measured by LDm/LDt. Term
placental villous explants remained viable over
the exposure period since the LDm/LDt ratio
was less than 5% (Fig. 4).
Immunolocalization of HO-1 and HO-2
Adsorption experiments with purified HO-1
and HO-2 proteins confirmed the binding
specificity of anti-HO-1 and anti-HO-2 anti-
bodies (data not shown). Consecutive sections
immunostained for -actin-1 confirmed that
the immunoreactive cells for HO-1 and HO-2
were of contractile nature. The HO-1 positivity
in the placenta was differently localized during
its developement (7, 9, 10, and 38 weeks) and
appeared correlated with the placental vascu-
larization (Fig. 5; Table 1). A perivascular stro-
mal staining for HO-1 was localized in the stro-
mal condensation of the villous core in early
pregnancy tissues, prior to the appearance of
vessels. The intensity of the positivity in-
creased with the development of muscularized
stem vessels and was most intense in term pla-
centae, in the chorionic plate and in the stem
villi arising from the plate (Fig. 5a–c). The 
intensity gradually declined with branching 
of the stem villi and was largely absent in 
villi devoid of muscularized vessels (Fig. 5;
Table 1). Fetal membranes showed strong 
immunoreactivity for the isozymes of HO. 
Immunostaining for HO-1 was most 
intense in chorio-decidua (Fig. 5d and e). No 
significant staining of the media or intima of
the chorionic and stem villous vessels was ob-
served. Staining of other components of the
placenta, such as trophoblast and villous 
stromal cells not closely related to blood 
vessels, was weak and inconsistent (Fig. 5;
Table 1).
The distribution and positivity for HO-2
was confined mainly to blood vessels, though
the trophoblastic brush border and the villous
stromal cells also showed a weak and irregular
staining (Fig. 5 f and g). In early pregnancy
(7–10 weeks), there was a specific staining of
the basal cytotrophoblast. In term placental
villi, there was an intense staining of the en-
dothelium of the terminal villous capillary bed,
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significantly attenuated by SnPP (Fig. 7C; p 
0.01; n 	 4).
Production of CO In Placenta and Fetal Membranes
To establish whether the HO-CO system was
functionally active within the human placenta,
villous fragments from term placentae were ex-
posed to hemin for up to 24 hr and CO produc-
tion was calculated by measuring the percent-
age of COHb in the conditioned media as
described in “Materials and Methods.” First-
trimester throphoblast cell line released CO into
Fig. 5. Immunolocalization of inducible heme
oxygenase (HO-1) and constitutive heme oxy-
genase (HO-2) in placental villi and feto-
placental membranes. Panel (a) shows first
trimester villi (7 weeks) and panel (b) shows pla-
cental villi at term (37 weeks), stained with anti-
HO-1 antibody. Strong staining for HO-1 is local-
ized in the perivascular villous stromal (VS) and
weaker staining in trophoblast layer (labelled “T”
and arrowhead in panel (a). Panel (c) shows in-
tense staining in the large blood vessels (V) of the
stem villi at term (38 weeks). Panels (d-e) show
very strong HO-1 staining in the chorio-decidual 
cells (“C”) and weak staining in the amnion (labelled
“A” and arrowhead in panel (e). Panels (f-g) show
HO-2 immunoreactivity. Intense staining of the en-
dothelium of the terminal villous capillary bed (C) at
term is shown in panel (f). In the endothelium of
large blood vessels (g) and the media of the muscu-
larized vessels, there is strong staining for HO-2.
Panel (h) shows staining with -actin in term pla-
centa. Magnifications: 350, panel c, e, g; 284,
panel a, b, d, f; and 142, panel h.
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Table 1. Degree of positivity for inducible heme oxygenase (HO-1) and constitutive heme oxygenase
(HO-2) immunostaining
HO-1 HO-2
Weeks of Gestation Weeks of Gestation
7 10 39 7 10 39
Trophoblastic brush border      
Syncytial trophoblast /     
Cytototrophoblast      
Villous stromal cells     / 
Perivascular stromal cells      
Stem vessel media      
Endothelium/intima   / / / 
Decidua      
Chorion      
Amnion /    / 
Immunoreactivity is expressed as slight (), moderate (), strong () and intense ().
Variable or equivocal staining (/). No staining ().
Fig. 6. The effect of hemin on vascular tension
in preconstricted placental arteries. Human pla-
cental arteries were preconstricted with 100 nM
U46619 (a thromboxane A2 mimetic) until steady
state of tension was achieved. Thereafter, 5 M
hemin or vehicle was added. A typical recording
trace showing the tension in response to hemin
(solid line) and to vehicle alone (dashed line) is
shown. The insert shows the effect of hemin at 30
min incubation timepoint on the mean change in
tension induced by U46619. Data represent the
mean  S.E.M. of five separate experiments. *p 
0.01 vs U46619.
tion. Preincubation with the HO inhibitor,
SnPP (20 M for 60 min), significantly attenuated
hemin-induced CO production in these villous
fragments (Fig. 8B; p  0.01, n 	 3). In fetal
membranes, after 2 hr incubation with hemin,
there was a significant increase in CO release
(Fig. 8C; p  0.01, n 	 3). In parallel experi-
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the culture medium; however, stimulation
with hemin did not potentiate CO production
(Fig. 8A). Figure 8B insert shows that hemin in-
duced a transient CO production in the villous
fragments (Fig. 8B; n 	 3). The CO release
peaked after 2 hr incubation with 5 M hemin,
but returned to basal values after 4 hr incuba-
Fig. 7. Effect of tin protoporphyrin IX (SnPP)
and NG-methyl-L-arginine (L-NMA) on hemin-
induced relaxation in the preconstricted pla-
cental arteries. Human placental arteries were pre-
constricted with 100 nM U46619 (a thromboxane
A2 mimetic) until steady state tension was achieved.
The change of tension was examined after adminis-
tration of each tested drug for 30 min. (A) Addition
of 5 M hemin to U46619-preconstricted arteries
after 30-min incubation in the presence of 20 M
SnPP did not significantly reduce tension. (B) Ad-
dition of 5 M hemin in the presence of 1 mM L-
NMA significantly reduced tension. The changes of
tension represent the mean  S.E.M. of five sepa-
rate experiments. *p  0.01 vs U46619. (C) Percent-
age reduction in tension U46619-preconstricted ar-
teries induced by hemin alone, hemin plus L-NMA
or hemin plus SnPP. *p  0.01 vs hemin.
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Fig. 8. Hemin mediated carbon monoxide release.
Tissue and cells were exposed to hemin and carbon
monoxide levels determined as a measure of the
percentage of carboxyhemoglobin (COHb) in the
media. (A) First-trimester trophoblasts were ex-
posed to 5 M hemin for up to 24 hr. (B) The effect
of HO inducer and HO inhibitor on CO production
in placental explants. Tissue was exposed to 20 M
SnPP (HO inhibitor) for 1 hr and then incubated
with 5 M hemin for 2 hr. An inset shows the 
effect of hemin (5 M) on CO production from 
term villous fragments over a 24-hr period. (C)
Fragments of chorio-decidua were exposed to 5 M
hemin for up to 24 hr. CO release is expressed 
as a percentage of carboxyhemoglobin (%COHb) in
the conditioned media and standardized per mg/ml
of total protein. Data are shown as the mean 
S.E.M. of three separate experiments performed 
in triplicate. *p  0.01 vs hemin; **p  0.001 vs 
vehicle.
ments, cell toxicity was evaluated as leakage of
LD in the media. Incubation with 5 M
hemin or with 20 M SnPP for 24 hr did not
increase LD leakage significantly, as measured
by LDm/LDt.
Discussion
HO-1 activation displays protective cellular ef-
fects through its enzymatic actions. One of its
products, bilirubin, displays anti-complement
(17) and anti-oxidant (34) effects; whereas, its
other product, CO, has anti-platelet and va-
sodilatatory properties (35,36). In vivo, HO-1
is implicated in the protection against endo-
toxin and hyperoxia-induced lung injury in
rats (37,38). Moreover, NO-induced protection
during myocardial ischemia and reperfusion
damage is dependent at least in part, on HO ac-
tivation (39).
Little is known about the role of endoge-
nous placental factors that may be responsible
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for counteracting the inflammatory response of
pregnancy. The studies described here provide
evidence that HO has a role in an endogenous
placental protective pathway for counteracting
physiopathological insults during pregnancy.
We demonstrate the presence of both isoforms
of HO in human placenta and show that the
HO-CO system offers cellular protection
against TNF-induced cytotoxic damage in the
placenta. The activation of HO-1 significantly
reduces TNF-mediated LD leakage from pla-
cental villous explants and the HO inhibitor,
SnPP, reverses the inhibitory effect of hemin on
TNF-mediated LD leakage, indicating HO se-
lective placental protection. One of the HO
products, bilirubin induces suppression of
hydrogen peroxide-mediated cell death in en-
dothelial cells in vitro (40) and HO inhibition
attenuates the cytoprotective effect of NO on
TNF cytotoxicity (41). Although TNF pre-
treatment confers resistance to hypoxic stress
in the adult cardiac myocyte (42), in the pla-
centa, it appears to cause cellular damage. It
was recently suggested that preeclampsia is a
disease of the exacerbation of an inflammatory
process characteristic of normal pregnancy, but
lacking a compensatory system (3). A number
of studies suggest that HO-1 acts as a potent
endogenous factor for the resolution of stress-
induced inflammatory injury (14–17). The 
present study provides molecular evidence for
the hypothesis that preeclampsia is a disease in
which the vascular protective factors that nor-
mally counteract the inflammatory process
characteristic of normal pregnancy are defec-
tive. It shows that HO-1 protein expression is
reduced in placental tissue obtained from preg-
nancies complicated by preeclampsia. This
suggests that HO protective pathway may be
ineffective for counteracting physiopathologi-
cal insults during pregnancy. Preeclampsia is
associated with reduced utero-placental circu-
lation, leading to poor placental perfusion that
results in local hypoxia and secretion of cyto-
toxic factors into the maternal circulation that
cause widespread circulatory disturbances sec-
ondary to endothelial dysfunction (1). It has
been speculated that acute hypoxia and inflam-
mation impair eNOS/NO production of the tro-
phoblast in vivo, which might contribute to
pathological conditions of gestational diseases
(26). Ihara and co-workers (43) showed that,
under acute fetal hypoxia, there was a decrease
in HO-1 mRNA in the rat placenta. Although
HO-1 mRNA levels did not change in placental
tissue from preeclamptic women, compared
with gestationally matched normal placenta,
the level of HO-1 protein were significantly re-
duced, suggesting a translational blockage.
Lipid peroxidation also was suggested as a
pathogenetic factor for preeclampsia, contribut-
ing to endothelial dysfunction (1). Lipid peroxi-
Fig. 8. (Continued)
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dation products like malonlidialdehyde are in-
creased and the activity of antioxidant enzymes,
superoxide dismutase and glucose 6-phosphate-
dehydrogenase are decreased in preeclamptic
placenta (44). One of the products of HO activa-
tion is bilirubin that is a lipid-soluble metabolite
of the body. Bilirubin was reported to act as 
a physiological chain-breaking antioxidant of
lipid peroxidation (34). A recent study showed
that the concentrations of total bilirubin in
pregnancy-induced hypertension were reduced
significantly, compared with normal pregnancy
(45). The results of the present study suggest that
the reduced bilirubin observed by Chandra and
colleagues (45) may be, in part, a result of de-
creased placental HO-1 activation in preeclamp-
tic placenta. In a human case of HO-1 deficiency,
there is severe, persistent endothelial damage, as
indicated by marked elevation in thrombomod-
ulin and von Willerand factor (8). It was sug-
gested that the induction of HO-1 directly regu-
lated endothelial cell activation as it prevented
the oxidative stress-induced expression of adhe-
sion molecules (9,10). Exposure of HO-1 knock-
out mice to hypoxia results in an increase in lipid
peroxidation and apoptosis in right ventricle of
the heart (46). The impairment of HO-1 activa-
tion in preeclamptic placenta could contribute to
the endothelial activation and cytotoxicity ob-
served in this pathology.
As in vivo angiogenesis is accompanied by
vasodilation, the release of second-messenger
gases such as NO and CO must regulate pla-
cental angiogenesis. NO is implicated in vascu-
lar remodeling (47). In placenta, the calcium-
dependent constitutive eNOS is localized in
the villous vascular endothelium and villous
syncytiotrophoblast (48,49) and the calcium-
independent inducible NOS isoform (iNOS) is
localized to the Hofbauer cells in villous
stroma, as well as in villous vascular endothe-
lium and syncytiotrophoblast (22). The current
study demonstrates the expression and distri-
bution of the two isozymes, HO-1 and HO-2, in
human placenta and fetal membranes through-
out gestation. RT-PCR analysis demonstrated
that first-trimester placenta, term placenta and
fetal membranes expressed mRNA encoding
both HO-1 and HO-2. Western blots analysis
showed that HO-1 (inducible) protein expres-
sion was markedly lower in the first-trimester
tissues, compared with the term placentae and
fetal membranes. In contrast, Rutherford and
colleagues (50) showed that eNOS protein was
significantly greater in first-trimester, com-
pared with normal term placentae (50). En-
dothelial cells transfected with the human HO-
1 gene increase growth and blood vessel for-
mation (36). The distribution of placental HO
isozymes, HO-1 and HO-2, show distinct topo-
graphic patterns. HO-1 is localized predomi-
nantly in the extravascular connective tissue
that forms the perivascular contractile sheath
around the developing blood vessels. HO-1 ex-
hibites a highly specific pattern of evolution
with placental vascularisation. A recent study
showed HO-1 immunoreactivity in the adven-
titial layer of the larger fetal blood vessels of
the guinea-pig placenta (51). In contrast, HO-2
isozyme was localized in the capilliaries as
well as the villous stroma, with weak staining
of trophoblast. The difference distribution of
HO-1 and HO-2 suggests that the HO isozymes
exhibit differential roles in placental vessel de-
velopment and regulation. In a recent study
Shaw-Fang and coworkers reported that in
HO-1 deficient mice, of the three characteristic
responses to hypoxia (vascular remodeling, hy-
pertension and hypertrophy of the right ventri-
cle), only the latter was evident (52). The 
authors suggested that CO released by HO-2
might be sufficient to balance for the lack 
of HO-1.
The feto-placental circulation lacks auto-
nomic innervation (18). The vasomotor regula-
tion of the smooth muscle cells surrounding
the villous arterioles plays a pivotal role in
maintaining the blood flow within the pla-
centa. A physiological role for NO in the regu-
lation of vascular tone was supported by the
observation that NO maintained low vascular
tone in the feto-placental circulation of the iso-
lated dual-perfused human cotyledon in vitro
(19,20). Furthermore, generation of NO ap-
pears to attenuate the effect of vasoconstrictors,
such as thromboxane A2 and endothelin-1 in
the placental circulation (21). The present
study shows that HO-CO system is a major
contributor for placental blood vessel relax-
ation. Activation of HO-1 by hemin causes
marked relaxation in precontricted villous arte-
rial rings that are prevented by HO inhibitor,
but not by NOS inhibitor, indicating a selective
action for hemin. Relaxation of placental arter-
ies and CO production by hemin occurs con-
comitantly, indicating that the HO-CO system
is active functionally within the placental vas-
culature. Placental and fetal membrane-
derived CO may, therefore, play a pivotal role
in the control of feto-placental vascular tone.
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Moreover, CO, like NO, inhibits platelet aggre-
gation (35) and could also act as a platelet anti-
aggregating agent in the utero-placental 
circulation. Localization of HO-1 to the
perivascular contractile sheath of developing
vessels and media of large stem vessels may 
indicate its importance for regulating feto-
placental circulation. The distribution of HO-2
suggests that it acts at the level of fetal capil-
liaries to prevent platelet adhesion and aggre-
gation. The present study clearly shows that
the NO-cGMP pathway is not the sole system
for maintaining low vascular tone in the feto-
placental circulation, as previously reported
(21,22). Indeed, NO induces HO-1 gene expres-
sion and CO production in vascular smooth
muscle cells (53). Although endothelial-derived
NO maintains normal resting blood vessel tone
(54), under hypoxia, NO production and eNOS
expression are suppressed (25,27) and the vessel
tone is  probably modulated by hypoxia medi-
ated factors. It is proposed that, while NO con-
tributes to the physiological regulation of vessel
tone, HO-CO pathway may act as a local regula-
tor of the feto-placental circulation under condi-
tions of hypoxia when NO levels are suppressed.
Fetal membranes are in close proximity to
the myometrium. Our previous study showed
that hemin inhibited oxytocin-induced myo-
metrial contractility (30). The present study
shows strong immunostaining for HO-1 in
chorio-decidua, increased expression of HO-1
protein, as well as hemin-induced CO produc-
tion from chorio-decidua. HO-1 activation in
fetal membranes may, therefore, contribute in
maintaining the uterus in a state of relative
quiescence during pregnancy. Clearly, the HO
pathway displays multifunctional roles in hu-
man pregnancy, depending on its tissue distri-
bution. Indeed, in early pregnancy, the expres-
sion of HO-1 and HO-2 in extravillous
trophoblast suggests a role for HO in uterine
vascular remodeling. In preeclampsia (55) and
in some cases of fetal growth restriction (56),
the uterine blood vessels do not undergo ade-
quate vascular transformation, due to the fail-
ure of trophoblast to successfully invade the
maternal spiral arterioles. A recent study in the
guinea-pig showed that increased dilation of
the utero-placental arteries due to NO release
was a prerequisite for trophoblast invasion and
remodeling of the endothelium (57). It was
proposed that the general ability of trophoblast
to penetrate the spiral arterioles in order to re-
model the endothelium may relate to the abil-
ity of local autocoids to stimulate NO. Failure
to generate adequate amounts of trophoblast-
derived NO may predispose women to
preeclampsia (58). In a recent abstract publica-
tion, Lyall and coworkers (59) reported im-
munohistochemical localization of HO isozymes
in extravillous trophoblast. Our finding that
first-trimester trophoblast in culture releases
CO suggests that trophoblast-derived CO may
aid trophoblast penetration into the spiral ar-
teries in early pregnancy. As basal CO levels are
elevated and hemin is unable to further induce
CO release from trophoblast cells, it suggests
that the HO pathway may be active in these cells.
The present study shows distinct topo-
graphic patterns of distribution for placental
HO isozymes and demonstrates that induction
of HO-1 offers protection against cytotoxic
damage. As activation of HO-1 promotes the
relaxation of placental vessels, the HO-CO sys-
tem may be acting as a local vasoregulator of
the feto-placental circulation and may be cru-
cial under conditions of hypoxia. The observed
reduced placental HO-1 expression by im-
munoblotting in preeclampsia may predispose
the placenta to cellular injury and subsequent
maternal endothelial cell activation. As
preeclampsia could be a disease of the exacer-
bation of an inflammatory process characteris-
tic of normal pregnancy, but lacking compen-
satory system, this reduction in placental HO-1
expression in preeclampsia suggests that the
impairment of HO-1 activation may compro-
mise the compensatory mechanism. It is likely
that other endogenous vascular protective sys-
tems exist that protect the mother from devel-
oping the symptoms of preeclampsia. If the
model is proven to be operational in vivo, it
may provide a useful new approach to the
study of this important disease.
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